Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Purpose
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Conditions
- Cancer
- Melanoma (Skin)
- Mismatch Repair Deficiency
- Microsatellite Instability
- Non-melanoma Skin Cancer
- Cutaneous Melanoma
- NSCLC
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. - At least one measurable and injectable lesion - Have provided a former tumor pathology specimen or be willing to supply a new tumor sample from a biopsy - Have a predicted life expectancy of ≥ 3 months - Measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria - Subjects with MSI-H or dMMR tumors: has diagnosis of MSI-H or metatstatic dMMR tumor (according to protocol definition) who has progressed on prior anti-PD1/PD-L1 therapy. - Subjects with NMSC: has diagnosis of locally advanced or metastatic NMSC that are not considered treatable by surgery including basal cell carcinoma, cutaneous squamous cell carcinoma, basosquamous carcinoma, Merkel cell carcinoma and other non-melanoma skin cancers (per protocol). Patients must have received 8 weeks of anti-PD1/PD-L1 as their last line of therapy and progressed while on treatment. - Subjects with anti-PD1 failed cutaneous melanoma: has confirmed progressive disease while on anti-PD1 treatment for at least 8 weeks and documented BRAF mutation status - Subjects with anti-PD1 failed NSCLC: must have failed prior treatment, including PD1/PD-L1 directed therapy administered either as monotherapy or in combination with platinum-based chemotherapy or anti-CTLA-4. The most recent treatment given must have included an anti-PD1/PD-L1 directed therapy with radiologic disease progression on or after treatment.
Exclusion Criteria
- Prior treatment with an oncolytic therapy - History of viral infections according to the protocol - Prior complications with herpes infections - Chronic use of anti-virals - Uncontrolled/untreated brain metastasis - History of interstitial lung disease - History of non-infectious pneumonitis - History of clinically significant cardiovascular disease
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Dose escalation of RP1 by intratumoral (IT) injection in superficial tumors |
Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors |
|
|
Experimental Dose escalation of RP1 by intratumoral (IT) injection in deep/visceral tumors |
Dose escalation of RP1 alone in 3 cohorts with IT injections in deep/visceral tumors |
|
|
Experimental Dose expansion of RP1 and nivolumab (IV) in superficial tumors |
Doses of RP1 (IT) in superficial tumors with nivolumab (IV) |
|
|
Experimental Dose expansion of RP1 and nivolumab (IV) in deep/visceral tumors |
Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV) |
|
|
Experimental RP1 (IT) and nivolumab (IV) in melanoma |
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma |
|
|
Experimental RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors |
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors |
|
|
Experimental RP1 (IT) and nivolumab (IV) in NMSC |
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer |
|
|
Experimental RP1(IT) and nivolumab (IV) in anti-PD1 Failed Cutaneous Melanoma |
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy |
|
|
Experimental RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NMSC |
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer who have been previously treated with anti-PD1/PD-L1 therapy |
|
|
Experimental RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NSCLC |
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non small cell lung cancer who have been previously treated with anti-PD1/PD-L1 therapy |
|
Recruiting Locations
More Details
- Status
- Recruiting
- Sponsor
- Replimune Inc.
Detailed Description
RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and to generate an anti-tumor immune response. This is a Phase 1/2, open label, multicenter, dose escalation and expansion, first-in-human (FIH) clinical study to evaluate the safety and tolerability, biodistribution, shedding, and preliminary efficacy of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors. The study will include a dose escalation phase for single agent RP1, an expansion phase with a combination of RP1 and nivolumab and a Phase 2 portion in specified tumor types for the combination therapy.